Radioiodine Plus Low-Dose Lenvatinib in Radioiodine-Sensitive High-Volume Metastatic Differentiated Thyroid Cancer: A Pilot Study.
Sign Up to like & getrecommendations! Published in 2025 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000006146
Abstract: BACKGROUND Radioactive iodine (RAI) therapy is the standard-of-care for metastatic differentiated thyroid cancer (DTC), but ~60% of patients show resistance before achieving satisfactory response. METHODS Eligible patients were randomly assigned to RAI therapy plus lenvatinib… read more here.
Keywords: rai; metastatic differentiated; rai arm; rai therapy ... See more keywords